SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

world map with red and orange colors over a dark color illustrations background
Manufacturing
Nascent US psychedelic therapy opportunity attracts overseas manufacturers
Companies that manufacture MDMA and psilocybin for patients in other countries are looking to use their experience to access the potential U.S. market.
August 14, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Email envelope with warning sign on white background
Manufacturing
Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
Despite earlier claims of improvement at the fill-finish plant, the FDA has classified the facility as Official Action Indicated based on inspection findings.
August 11, 2026
 · 
2 min read
 · 
Nick Paul Taylor
High angle night view of the city skyline at Huaian Bridge in Shijiazhuang, Hebei Province, China
Manufacturing
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
News of the joint venture comes months after AstraZeneca vowed to spend $15 billion in China by the end of the decade.
August 10, 2026
 · 
2 min read
 · 
Nick Paul Taylor
A crushing blow to business and economic growth. Stopping income rise and welfare growth. Mitigate dangers and reduce risks. Anticipate the main blow of the crisis. End of career. Bankruptcy.
Earnings
BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine
Lower vaccine demand across every market and more acute pressures in Germany led BioNTech to lower the midpoint of its sales outlook by almost 20%.
August 4, 2026
 · 
2 min read
 · 
Nick Paul Taylor
3D rendering of a GLP-1 agonist injector pen, a weight loss medication, with a medical measuring tape or ruler spiraling dynamically around its form.
Deals
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
The investment will expand Resilience’s U.S. capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines.
July 31, 2026
 · 
1 min read
 · 
Nick Paul Taylor
Pandoras box with smoke on a wooden background
Earnings
Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
Calls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.
July 30, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Two connecting arrows symbolizing artificial intelligence and humans working together to achieve a common goal, isolated on a light digital abstract background. Vector illustration.
Manufacturing
Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR T therapy
ElevateBio will be the primary source of Kyverna’s autologous CAR T cell therapy for anticipated U.S. and global launches in autoimmune indications.
July 29, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Business handshake trendy halftone art collage banner template. Partnership concept, successful agreement, closing a deal, securing a contract. Modern retro cut out vector illustration
Manufacturing
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
Top-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.
July 22, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Successful businessman throwing green line graph arrow to hit target on rising banknotes bar graph for financial growth profit and cash flow investment achievement concept
Business
Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
With a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.
July 22, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Big fish eats small, takeover of the company. Art collage.
Manufacturing
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
With PolyPeptide manufacturing peptides such as GLP-1 medicines, Samsung Biologics has identified the deal as a way to tap into fast-growing demand for obesity drug production services.
July 21, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Art collage, Two hands are shown holding a legal document and a gavel, with scales of justice in the center. The colorful background enhances the theme of law and order, highlighting the importance of justice.
Complete response letters
FDA’s radical transparency policy for rejections runs into legal uncertainty
Having started to publish CRLs without consulting the public, the FDA is under pressure to change course amid concerns it failed to openly and fully evaluate a complex issue.
July 20, 2026
 · 
5 min read
 · 
Nick Paul Taylor
Baseball background design. Vector illustration of sports concept
Manufacturing
Manufacturing issues prompt FDA to reject Hengrui-Elevar filings for third time
An inspection of a facility making Elevar’s rivoceranib uncovered deficiencies, leading the FDA to reject a combination therapy that includes the drug. The rebuff is the third strike for the partners after the agency issued manufacturing-related denials for the other drug in the combo.
July 15, 2026
 · 
1 min read
 · 
Nick Paul Taylor
Project management vector icon. Pixel perfect vector graphics
Manufacturing
FDA proposes streamlined requirements for ‘hub-and-spoke’ manufacturing models
Through the proposal, the FDA could clear barriers to distributed manufacturing approaches intended to enhance emergency preparedness and supply chain resilience.
July 14, 2026
 · 
2 min read
 · 
Nick Paul Taylor
A plastic orange prescription drugs container with white and blue pills, a magnifying glass zooming in on the label
Regulatory
Amgen continues to defend Tavneos as global regulatory pressure mounts
Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the medicine, which was acquired in the $3.7 billion buyout of ChemoCentryx.
July 10, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Horizontal photo collage picture of people arms in gloves hold work instrument equipment hammer brush nail gun isolated on blue background.
Artificial intelligence
Biopharma R&D needs ‘structural redesign’ to maximize AI impact: report
Biopharma companies won’t fully capture the benefits of AI unless they reorganize their R&D units, according to McKinsey.
July 9, 2026
 · 
2 min read
 · 
Nick Paul Taylor